Trans-complementation defective monkeypox virus and its application

By constructing a trans complementary defective monkeypox virus system, the safety and effectiveness of monkeypox virus research in the existing technology under low biosafety conditions was solved, and the research on simulating the real viral infection process in a specific cell line was realized. It reduces the risk of homologous recombination and provides a safe drug screening and evaluation platform.

CN117264909BActive Publication Date: 2024-11-26SHENZHEN BAY LAB +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202311394116.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-10-25
Publication Date
2024-11-26
Estimated Expiration
2043-10-25

AI Technical Summary

Technical Problem

The prior art is difficult to conduct basic research on high pathogenicity of monkeypox virus and drug screening evaluation under low biosafety conditions, and there is a lack of an effective trans complementary defective virus system to simulate the real viral infection process and reduce the risk of homologous recombination.

Method used

Construct a trans complementary defective monkeypox virus system, by deleting multiple viral replication and proliferation essential gene regions, introducing recombinant lethal elements, forming defective viruses with almost the same physical and chemical properties, which are used to express non-structural proteins in specific cell lines and simulate The real viral infection process.

Benefits of technology

The genetic evolution and pathogenic mechanism of monkeypox virus were carried out under low biosafety conditions, reducing the risk of virus leakage, providing a safe drug screening and evaluation platform, and enhancing the safety and effectiveness of the research.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117264909B_ABST
    Figure CN117264909B_ABST
Patent Text Reader

Abstract

The present application discloses a trans-complementation defective monkeypox virus and its application. In the first aspect of the present application, a biomaterial is provided, which can be an isolated nucleic acid molecule, including the nucleic acid sequence of the whole genome of the monkeypox virus, and the nucleic acid sequence lacks multiple genes. The progeny defective virus produced by the monkeypox trans-complementation system constructed using the nucleic acid molecule is almost the same as the real live virus in physical and chemical properties. In the complementary cell line, the whole process of virus invasion, replication and packaging release can be completed, which has a natural advantage over other virus systems. While ensuring safety, various basic research on monkeypox virus can be carried out, and anti-monkeypox virus drug screening, neutralizing antibody evaluation, vaccine protection evaluation and attenuated vaccine development can be carried out.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the field of virus technology, and in particular to a trans-complementation-deficient monkeypox virus and its application. Background Art

[0002] The monkeypox virus is a close relative of the smallpox virus. Its genome is double-stranded DNA, nearly 200kb in length. The virus has an envelope, about 200-300nm in diameter, brick-shaped, and a dumbbell-shaped core. The natural hosts of the monkeypox virus in nature are rodents and other mammals, and it is mainly transmitted through close contact. After infection with the monkeypox virus, a large rash will appear on the surface of the skin, accompanied by fever, muscle aches and other symptoms. There is currently no dedicated vaccine or therapeutic antibody for the monkeypox virus. The smallpox vaccine has a certain preventive and protective effect on monkeypox, but it has greater side effects for certain populations. There are no commercial anti-monkeypox drugs and vaccines in China.

[0003] Monkeypox virus has a high homology with smallpox virus and vaccinia virus of the orthopoxvirus genus, but also encodes many specific proteins of its own. At present, the research on the relationship between monkeypox virus and the host after infection is still insufficient. In virological research, wild-type live virus is the "gold standard" for genetic evolution and pathogenic mechanism research, drug screening and efficacy evaluation. Monkeypox virus has a high transmission ability and pathogenicity. Its live virus research must be carried out in biosafety level 3 and above facilities, requiring skilled technical operators and complex safety protection equipment. Direct research on wild live monkeypox virus has additional risks of virus leakage, and an efficient and safe research platform is urgently needed to clarify the pathogenic mechanism of monkeypox virus in the host.

[0004] The most commonly used high-security virus systems include virus subreplicons, pseudovirus systems, and virus-like particles (VLPs). Virus subreplicons can only study the replication and amplification of viruses in cells. Pseudovirus systems play an important role in antibody / antiserum neutralization studies of mutant viruses, but the double membrane structure of monkeypox virus has more than 50 surface proteins, and pseudovirus systems cannot simulate the structure of the surface of monkeypox virus. Although virus-like particles (VLPs) can produce structures similar to the surface of real viruses, they cannot be used to study the interaction between viruses and hosts in cells after infection.

[0005] The trans-complementation defective virus system is a high-quality virus platform for conducting basic research on highly pathogenic viruses and drug screening and evaluation under low biosafety conditions. The defective virus in this system lacks multiple essential gene regions for viral replication and proliferation, and can only produce progeny defective viruses in specific cell lines that complement these essential genes. However, unlike the VLP system, the trans-complementation defective virus maintains the integrity of other viral genomes as much as possible, and its virus particles have almost the same physical and chemical properties as wild-type live viruses; after the defective virus infects the complemented cells, all non-structural proteins of the virus can be expressed, which is convenient for studying their correlation with various signal pathways in the host; it can also simulate the entire process that is closest to real virus infection in drug screening. The trans-complementation system often lacks essential genes in different locations and physiological stages of multiple viruses to reduce the risk of wild-type reversion of the virus through homologous recombination; at the same time, recombinant lethal elements are introduced to further increase the safety of the virus; the safety of a variety of trans-complementation defective viruses has been fully verified in cell and animal models.

[0006] Therefore, it is necessary to establish a trans-complementation defective virus system for monkeypox virus for basic research on the genetic evolution of monkeypox virus, its interaction with the host, and the screening and evaluation of anti-monkeypox drugs. Summary of the invention

[0007] The present application aims to solve at least one of the technical problems existing in the prior art. To this end, the present application proposes a trans-complementation defective monkeypox virus system, which can be used for basic research on the genetic evolution of monkeypox virus and its interaction with the host, and for the screening and evaluation of anti-monkeypox drugs.

[0008] In the first aspect of the present application, a biological material is provided, which is selected from any one of the following A1) to A9): A1) an isolated nucleic acid molecule, comprising a nucleic acid sequence of the whole genome of a monkeypox virus, wherein the nucleic acid sequence lacks multiple genes; A2) an expression cassette comprising the nucleic acid molecule described in A1); A3) a vector comprising the nucleic acid molecule described in A1); A4) a vector comprising the expression cassette described in A2); A5) a cell comprising the nucleic acid molecule described in A1); A6) a cell comprising the expression cassette described in A2); A7) a cell comprising the vector described in A3); A8) a cell comprising the vector described in A4); A9) a defective monkeypox virus produced by culturing the cells described in any one of A5) to A8).

[0009] In some embodiments, the GenBank accession number of the nucleic acid sequence of the whole genome of the monkeypox virus in the biological material is ON563414.3.

[0010] In some embodiments, any two adjacent genes among the multiple genes are at least 1000nt, 2000nt, 5000nt, 10000nt, 12000nt, 15000nt, 20000nt, 25000nt, or 30000nt apart in the nucleic acid sequence of the whole genome.

[0011] In some embodiments, the plurality of genes include essential genes for poxvirus infection and replication. In some embodiments, the plurality of genes include highly conserved genes for poxviruses. In some embodiments, the plurality of genes include essential genes for viral cell entry and protein expression.

[0012] In some embodiments, the multiple genes include at least one of a mid-stage transcription factor and a late-stage transcription factor. In some embodiments, the multiple genes deleted in the nucleic acid sequence include at least two, at least three, or all four of G9R, A9R, A24R, and A1L. In some embodiments, the multiple genes deleted in the nucleic acid sequence include at least one of A9R, A24R, and A1L and G9R. In some embodiments, the multiple genes deleted in the nucleic acid sequence include G9R and A9R, G9R and A24R, G9R and A1L, G9R, A9R and A24R, G9R, A9R and A1L, G9R, A24R and A1L, G9R, A9R, A24R, and A1L.

[0013] Among them, G9R (VLTF-1) is a late gene transcription factor gene, similar to the G8R gene of the Copenhagen strain of vaccinia virus; A9R is a subunit of the intermediate transcription factor (VITF-3), similar to the A8R gene of the Copenhagen strain of vaccinia virus; A24R is also a subunit of the intermediate transcription factor (VITF-3), similar to the A23R gene of the Copenhagen strain of vaccinia virus; A1L (VLTF-2) is a late gene transcription factor gene, similar to the A1L gene of the Copenhagen strain of vaccinia virus.

[0014] In some embodiments, the nucleic acid sequence is inserted into a first reporter gene at the knockout position of the most upstream deleted gene, and / or, a second reporter gene is inserted downstream of the most downstream deleted gene.

[0015] In some embodiments, the most upstream deleted gene is G9R. In some embodiments, the most downstream deleted gene is any one of A9R, A24R and A1L.

[0016] In some embodiments, the nucleic acid sequence is inserted into a first reporter gene at the G9R knockout position, and / or, a second reporter gene is inserted downstream of A24R. In some embodiments, the nucleic acid sequence is inserted into a first reporter gene at the G9R knockout position, and / or, a second reporter gene is inserted downstream of A1L.

[0017] In some embodiments, the first reporter gene and the second reporter gene are different fluorescent reporter genes. In some embodiments, the fluorescent bands of different fluorescent reporter genes are different. In some embodiments, the first reporter gene and the second reporter gene are mCherry and mNeonGreen, or mNeonGreen and mCherry, respectively.

[0018] The second aspect of the present application provides a trans-complementation-deficient monkeypox virus system, which comprises: the aforementioned biological material; and complementing cells, wherein the complementing cells express multiple genes deleted in the biological material.

[0019] In some embodiments, any two adjacent genes among the multiple genes are at least 1000nt, 2000nt, 5000nt, 10000nt, 12000nt, 15000nt, 20000nt, 25000nt, or 30000nt apart in the nucleic acid sequence of the whole genome.

[0020] In some embodiments, the multiple genes include essential genes for poxvirus infection and replication. In some embodiments, the multiple genes include highly conserved genes for poxviruses. In some embodiments, the multiple genes include essential genes for viral cell entry and protein expression. In some embodiments, the multiple genes include at least one of a mid-transcription factor and a late transcription factor. In some embodiments, the multiple genes deleted from the nucleic acid sequence include at least two, at least three, or all four of G9R, A9R, A24R, and A1L. In some embodiments, the multiple genes deleted from the nucleic acid sequence include at least one of A9R, A24R, and A1L and G9R. In some embodiments, the multiple genes deleted from the nucleic acid sequence include G9R and A9R, G9R and A24R, G9R and A1L, G9R, A9R and A24R, G9R, A9R and A1L, G9R, A24R and A1L, G9R, A9R, A24R, and A1L.

[0021] In some embodiments, the biological material comprises cells of the nucleic acid molecule or the expression cassette or the vector. In some embodiments, the biological material comprises defective monkeypox virus produced by the above cell culture. In some embodiments, the anaplerotic cell is a prokaryotic cell or a eukaryotic cell. In some embodiments, the anaplerotic cell is a mammalian cell.

[0022] In some embodiments, the replenishing cells include at least one of Vero (such as Vero and Vero E6), Caco2, MRC5, RK13, LLC-MK2, Huh7 (such as Huh7, Huh7.5, Huh7.5.1-8), SW13, 15P-1, A549, 293T, Neuro-2a, OVCAR3, Hela, 22RV1, PSCH, HTR-8, SK-OV-3, HCT-8, JEG-3, BeWo, H295R, DU145, HUT-78, SK-Mel-28, etc.

[0023] The third aspect of the present application provides a method for preparing a replication-defective monkeypox virus, the method comprising the following steps: infecting complementing cells with the defective monkeypox virus to rescue the replication-defective monkeypox virus; the defective monkeypox virus lacks multiple genes, and the complementing cells express the multiple genes.

[0024] In some embodiments, any two adjacent genes among the multiple genes are at least 1000nt, 2000nt, 5000nt, 10000nt, 12000nt, 15000nt, 20000nt, 25000nt, or 30000nt apart in the nucleic acid sequence of the whole genome.

[0025] In some embodiments, the multiple genes include essential genes for poxvirus infection and replication. In some embodiments, the multiple genes include highly conserved genes for poxviruses. In some embodiments, the multiple genes include essential genes for viral cell entry and protein expression. In some embodiments, the multiple genes include at least one of a mid-transcription factor and a late transcription factor. In some embodiments, the multiple genes deleted from the nucleic acid sequence include at least two, at least three, or all four of G9R, A9R, A24R, and A1L. In some embodiments, the multiple genes deleted from the nucleic acid sequence include at least one of A9R, A24R, and A1L and G9R. In some embodiments, the multiple genes deleted from the nucleic acid sequence include G9R and A9R, G9R and A24R, G9R and A1L, G9R, A9R and A24R, G9R, A9R and A1L, G9R, A24R and A1L, G9R, A9R, A24R, and A1L.

[0026] In some embodiments, the defective monkeypox virus is prepared by a method comprising the following steps: knocking out the multiple genes from the full-length gene of the monkeypox virus and inserting a reporter gene to obtain the full-length gene of the defective monkeypox virus; splitting the full-length gene of the defective monkeypox virus, designing primers for amplification respectively, and cloning them into recombinant vectors respectively by homologous recombination; after enzyme digestion of the recombinant vector, connecting with a ligase to obtain a full-length clone of the whole genome of the monkeypox virus with the multiple genes knocked out; transfecting the full-length clone into cells to obtain the defective monkeypox virus.

[0027] In some embodiments, the multiple genes are knocked out from the full-length gene of the monkeypox virus, and a reporter gene is inserted to obtain a defective full-length gene of the monkeypox virus, including: knocking out the multiple genes from the full-length gene of the monkeypox virus, inserting a first reporter gene sequence at the site of the knocked-out upstream gene, inserting a second reporter gene sequence at the start site of the knocked-out downstream gene, and connecting the knocked-out downstream gene through a self-cleavage sequence.

[0028] In some embodiments, the proteins expressed by the first reporter gene and the second reporter gene have different fluorescence bands. In some embodiments, the first reporter gene and the second reporter gene are fluorescent protein genes of different bands. In some embodiments, the first reporter gene and the second reporter gene are mCherry and mNeonGreen genes, or mNeonGreen and mCherry genes, respectively.

[0029] In some embodiments, the self-cleavage sequence is a 2A peptide sequence.

[0030] In some embodiments, the defective monkeypox virus full-length gene is split, primers are designed to amplify them respectively, and they are cloned into recombinant vectors respectively by homologous recombination, including: splitting the defective monkeypox virus full-length gene into gene fragments with a length of 1000-5000bp, and designing amplification primers respectively; amplifying the gene fragments using the amplification primers to obtain different amplification products; cloning the amplification products into the recombinant vector by homologous recombination to obtain 5 to 10 recombinant vectors containing different spliced ​​fragments with a length of 1 to 20kb.

[0031] In some embodiments, the full length of the monkeypox virus is split into several gene fragments with lengths of approximately 1 kb, 2 kb, 3 kb, 4 kb, and 5 kb, and amplification primers are designed for each of them.

[0032] In some embodiments, the amplified product is cloned into a recombinant vector by homologous recombination to obtain 5, 6, 7, 8, 9, or 10 recombinant vectors containing different spliced ​​fragments of approximately 1 kb, 2 kb, 3 kb, 4 kb, 5 kb, 6 kb, 7 kb, 8 kb, 9 kb, 10 kb, 11 kb, 12 kb, 13 kb, 14 kb, 15 kb, 16 kb, 17 kb, 18 kb, 19 kb, 20 kb, 21 kb, 22 kb, 23 kb, 24 kb, 25 kb, 26 kb, 27 kb, 28 kb, 29 kb, or 30 kb in length.

[0033] In some embodiments, the amplified product is cloned into a recombinant vector and then integrated into multiple spliced ​​fragments by Gibson assembly and yeast in vivo recombination. In some embodiments, the amplification primers are shown in SEQ No. 1-112.

[0034] In some embodiments, the complementing cells are prepared by a method comprising the following steps: inserting several genes among the multiple genes of the monkeypox virus into a first lentiviral vector for packaging after codon optimization, collecting the first lentivirus and infecting the first cells, and screening to obtain the first cells expressing the several genes; inserting the remaining genes among the multiple genes of the monkeypox virus into a second lentiviral vector for packaging after codon optimization, collecting the second lentivirus and infecting the first cells expressing the several genes, and screening to obtain the complementing cells.

[0035] In some embodiments, the several genes are at least one of A9R, A24R and A1L; the remaining gene is G9R. In some embodiments, the several genes are A9R and A24R, or A1L; the remaining gene is G9R.

[0036] In some embodiments, the full-length clone is transfected into cells by a transfection reagent, and under the action of poxvirus RNA transcriptase, defective monkeypox virus is obtained in the transfected cells. In some embodiments, after a large number of cells have pathological changes, the supernatant containing the P0 generation defective monkeypox virus and the cells containing the P0 generation defective monkeypox virus are collected. After the cells are broken, they are re-infected on the complementing cells, and after a large number of cells have pathological changes, the P1 generation defective monkeypox virus is collected.

[0037] The fourth aspect of the present application provides a replication-defective monkeypox virus prepared according to any of the aforementioned preparation methods.

[0038] In some embodiments, the replication-defective monkeypox virus comprises the P1 generation defective monkeypox virus obtained above.

[0039] The fifth aspect of the present application provides the use of the aforementioned biological material, or the aforementioned trans-complementation defective monkeypox virus system, or the aforementioned replication-deficient monkeypox virus in any one of the following B1) to B7): B1) preparing products for screening anti-monkeypox virus drugs; B2) screening anti-monkeypox virus drugs; B3) preparing products for evaluating the efficacy of anti-monkeypox virus drugs; B4) evaluating the efficacy of anti-monkeypox virus drugs; B5) preparing products for studying the genetic evolution and pathogenic mechanism of monkeypox virus; B6) studying the genetic evolution and pathogenic mechanism of monkeypox virus; B7) preparing drugs or vaccines for preventing and / or treating monkeypox virus.

[0040] In some embodiments, the above application is for non-disease diagnosis or treatment purposes.

[0041] In the embodiments of the present application, a defective monkeypox virus genome lacking multiple essential genes for monkeypox virus infection and proliferation is used. Based on the research results on various orthopoxviruses such as vaccinia virus, G9R and A9R and A24R or A1L genes on monkeypox virus are selected as knockout targets. These genes have been shown to be essential genes for infection and replication of the poxvirus family. The deletion of any one of these genes will cause poxvirus lethality. Among them, the G9R and A1L genes of monkeypox virus encode a late transcription factor, which is highly conserved in all poxviruses. Poxviruses with defects in G9R and / or A1L genes cannot initiate viral cell entry. The heterodimer formed by the A9R gene and the A24R gene encoding is the mid-term transcription factor of the monkeypox virus. The deletion of any of these two genes will cause the blocking of the expression of the mid-term protein of the poxvirus. These essential genes of monkeypox virus are distributed in different positions on the monkeypox virus, which will further reduce the risk of homologous recombination of the virus returning to the wild type. Through reverse genetics, a defective monkeypox genome lacking multiple essential poxvirus genes was constructed, and the defective monkeypox virus was rescued in a multi-gene complementation cell line for subsequent research on the genetic evolution and pathogenic mechanism of monkeypox virus.

[0042] Additional aspects and advantages of the present application will be given in part in the description below, and in part will become apparent from the description below, or will be learned through the practice of the present application. BRIEF DESCRIPTION OF THE DRAWINGS

[0043] Figure 1 The results of screening and identification of defective monkeypox virus complementing cell lines in one embodiment of the present application are shown in Figure 1. A is the expression of G9R, A9R and A24R genes in the three-gene complementing cell lines detected by Western Blot; and B is the expression ratio and location of each complementing gene in the cells detected by IFA staining.

[0044] Figure 2 The results of constructing a bacterial / yeast shuttle vector in an embodiment of the present application are shown in Figure 1. In Figure 1, a is a vector map. In Figure 1, the left lane M is a molecular weight marker, and the right lane is a 1718 bp target band obtained by digestion with SalI and HpaI after the yeast YAC gene element is inserted into the pSMART-Bac2.0 plasmid.

[0045] Figure 3 This is the result of MPV-F1 to MPV-F7 (respectively a to g) gene fragment cloning, assembly and identification in one embodiment of the present application. Among them, the leftmost lane M in a to g is a molecular weight marker (Marker), lanes 1 to 10 in a are the bands of Bac-F1, F1ab, F1bc, F1cd, F1de, F1ef, F1fg, F1gh, F1hi, and F1i-Bac, lanes 1 to 9 in b are the bands of Bac-F2, F2ab, F2bc, F2cd, F2de, F2ef, F2fg, F2gh, and F2h-Bac, lanes 1 to 8 in c are the bands of Bac-F3, F3ab, F3bc, F3cd, F3de, F3ef, F3fg, and F3g-Bac, and lanes 1 to 9 in d are the bands of Bac-F4, The bands of F4ab, F4bc, F4cd, F4de, F4ef, F4fg, F4gh, and F4h-Bac are shown in Figure 5; lanes 1 to 9 in e are bands of Bac-F5, F5ab, F5bc, F5cd, F5de, F5ef, F5fg, F5gh, and F5h-Bac, respectively; lanes 1 to 9 in f are bands of Bac-F6, F6ab, F6bc, F6cd, F6de, F6ef, F6fg, F6gh, and F6h-Bac, respectively; lanes 1 to 9 in g are bands of Bac-F7, F7ab, F7bc, F7cd, F7de, F7ef, F7fg, F7gh, and F7h-Bac, respectively.

[0046] Figure 4This is the result of MPV subclone digestion identification in an example of the present application. The lanes M on both sides are molecular weight markers, lanes 1 to 7 are the identification results of MPV-F1 to MPV-F7, the lower band is the vector, and the upper band is the MPV subgene clone DNA fragment.

[0047] Figure 5 The splicing result of the defective monkeypox virus full-length genome in one embodiment of the present application. Among them, a is a schematic diagram of the splicing of the genome, in which the essential genes G9R, A9R and A24R are missing from the spliced ​​MPV-F1 to MPV-F7, and the mCherry and mNeonGreen reporter genes are introduced; b is a schematic diagram of the assembly of a single fragment in MPV-F1 to MPV-F7; c is a PCR amplification of the gene fragment covering the fragment connection site, and the integrity of the full-length genome connected in vitro is verified by sequencing.

[0048] Figure 6 The rescue result of the triple knockout defective monkeypox virus in one embodiment of the present application is shown in Figure 1. Among them, a is a schematic diagram of the rescue strategy of the defective monkeypox virus, and b is the fluorophore of the plaque formed after virus transfection.

[0049] Figure 7 The result of immunoblotting in one example of the present application is shown in FIG. 1 , wherein the lanes from left to right are molecular weight marker M (Marker), control group, and infection group.

[0050] Figure 8 This is the safety identification result of the replication-defective monkeypox virus in one example of the present application. DETAILED DESCRIPTION

[0051] The following will clearly and completely describe the concept of the present application and the technical effects produced in combination with the embodiments, so as to fully understand the purpose, features and effects of the present application. Obviously, the described embodiments are only part of the embodiments of the present application, not all of them. Based on the embodiments of the present application, other embodiments obtained by those skilled in the art without creative work are all within the scope of protection of the present application.

[0052] The embodiments of the present application are described in detail below. The described embodiments are exemplary and are only used to explain the present application, and should not be understood as limiting the present application.

[0053] In the description of this application, "several" means more than one, "more" means more than two, "greater than", "less than", "exceed", etc. are understood to exclude the number itself, and "above", "below", "within", etc. are understood to include the number itself. If there is a description of "first" or "second", it is only used for the purpose of distinguishing technical features, and cannot be understood as indicating or implying relative importance or implicitly indicating the number of the indicated technical features or implicitly indicating the order of the indicated technical features.

[0054] Unless otherwise defined, all technical and scientific terms used in this application have the same meaning as those commonly understood by those skilled in the art to which this application belongs. The terms used herein are only for the purpose of describing the embodiments of this application and are not intended to limit this application.

[0055] In the description of the present application, the description with reference to the terms "one embodiment", "some embodiments", "illustrative embodiments", "examples", "specific examples", or "some examples" means that the specific features, structures, materials, or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present application. In this specification, the schematic representation of the above terms does not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials, or characteristics described may be combined in any one or more embodiments or examples in a suitable manner.

[0056] Example 1: Establishment of a cell line with essential genes of monkeypox virus

[0057] The A9R gene and A24R gene of monkeypox virus (MPV, GenBank: ON563414.3) were codon-optimized and inserted into the pLVX-Puromycin lentiviral vector (the A9R gene and A24R gene were added with V5 tags and HA tags, respectively), and co-transfected with the helper plasmid on 293T cells for lentiviral packaging. After 48 hours, the lentivirus was collected and infected with Vero E6 cells, and Puromycin was used for screening to obtain a Vero cell line with stable expression of the A9R gene and A24R gene.

[0058] The G9R gene of the monkeypox virus (GenBank: ON563414.3) was codon-optimized and inserted into the pLVX-Blasticidin lentiviral expression vector (with a Flag tag) and the auxiliary plasmid for lentiviral packaging on 293T cells. After 48 hours, the lentivirus expressing the G9R gene was collected and infected with the Vero cell line stably expressing the A9R gene and the A24R gene. Puromycin and Blasticidin were used for screening to obtain a triple complementation gene cell line.

[0059] The cell lines with the three complementing genes were screened and protein expression was identified using Western Blot and IFA. Figure 1 As shown in the figure, it can be seen that G9R, A9R and A24R in the triple complementation gene cell line have higher expression levels.

[0060] Example 2: Design and assembly of a full-length defective monkeypox genome

[0061] The full-length defective monkeypox virus was designed and constructed using the Massachusetts strain MA001, GenBank: ON563414.3, as a template. The full-length gene of the monkeypox virus was first deleted by deleting the three genes G9R, A9R and A24R. The mCherry reporter gene sequence was inserted into the G9R gene site so that the mCherry fluorescent protein could be expressed with the help of the G9R promoter. The mNeonGreen reporter gene was introduced into the A46R gene start site, and the A46R gene was connected through the FMDV 2A self-cleavage sequence, so that the mNeonGreen fluorescent protein and the A46R protein could be separated after being expressed in series by FMDV 2A self-cleavage. Among them, for experimental observation and identification, the mCherry gene was introduced after the G9R gene was knocked out, and the mNeonGreen gene was inserted and co-expressed with the A46R gene after the A46R gene promoter was transcribed in the late stage of the monkeypox virus (the two proteins were directly connected using FMDV 2A). The 197kb genome of the monkeypox virus was split into 57 gene fragments (the gene fragment size was 3-5kb) and gene synthesis was performed separately. The MPV subgene cloned DNA fragments were spliced ​​into 7 large fragments (F1-F7) by yeast homologous recombination, and the correct MPV gene subclones were transferred into bacteria for amplification and culture. Finally, the F1-F7 genome fragments were cut out using restriction endonucleases, and connected into the MPV full-length defective genome in vitro by T4 ligase, and verified by inter-fragment PCR and whole genome sequencing. The specific steps are as follows:

[0062] 1. Construction of bacterial / yeast shuttle vector

[0063] refer to Figure 2, an artificially synthesized yeast artificial chromosome gene fragment is introduced between the bacterial artificial chromosome vector pSMART-BAC 2.0 endonuclease sites SalI and HpaI to form a vector (pSMART-BAC / YAC) that can shuttle between bacteria and yeast. The yeast artificial chromosome gene fragment contains a yeast molecular screening marker TRP, a yeast autonomous replication element ARS, and a centromere sequence CEN, so that the bacterial artificial chromosome has the characteristics of being able to replicate and shuttle in bacteria and yeast respectively. By enzyme digestion at the SalI and HpaI sites, a target band of 1718bp can be obtained, indicating that the bacteria / yeast shuttle vector is successfully constructed. The constructed shuttle vector is linearized by plasmid enzyme digestion, and yeast assembly of MPV viral DNA fragments can be performed.

[0064] 2. MPV viral gene fragment cloning and assembly

[0065] 2.1 Cloning and assembly of MPV-F1 gene fragments

[0066] The plasmid containing the full-length genome sequence of monkeypox virus (GenBank: ON563414.3) after three genes were knocked out and fluorescent protein was knocked in was used as a template. The 9 pairs of primers in the table below were used for PCR amplification using Q5 High-Fidelity DNA Polymerase. The PCR reaction system was: 98°C for 5 min, 98°C for 10 s, 65°C for 30 s, 72°C for 3 min, 72°C for 5 min, and 35 cycles. The obtained amplified product was subjected to 1% agarose gel electrophoresis (SYBR Safe DNA Gel Stain, 10,000×), and the target DNA fragment was recovered using the OMEGA Gel Extraction Kit, and the concentration was determined. The obtained 9 PCR products and the shuttle vector were added to a centrifuge tube in equal proportions and lysed according to the Yeastmaker method. TM The steps of Yeast Transformation System 2 require transformation of yeast for in vivo recombination, plating on SD / -trp plates and culturing at 30°C.

[0067]

[0068]

[0069] 2.2 Cloning and assembly of MPV-F2 gene fragments

[0070] Using the synthesized plasmid as a template, use the 8 pairs of primers in the table below to amplify with Q5 High-Fidelity DNA Polymerase PCR. The PCR reaction system is: 98°C 5min, 98°C 10s, 65°C 30s, 72°C 3min, 72°C 5min, 35 cycles. The obtained amplified product was subjected to 1% agarose gel electrophoresis (SYBR Safe DNA Gel Stain, 10,000×), and the target DNA fragment was recovered using the OMEGA Gel Extraction Kit, and the concentration was determined. The obtained 8 PCR products and the shuttle vector were added to a centrifuge tube in equal proportions, and the Yeastmaker TM The steps of Yeast Transformation System 2 require transformation of yeast for in vivo recombination, plating on SD / -trp plates and culturing at 30°C.

[0071]

[0072] 2.3 Cloning and assembly of MPV-F3-G9R-KO-mCherry gene fragment

[0073] Using the synthesized plasmid as template, use the 7 pairs of primers in the table below and use 2×Platinum TM SuperFi TM II PCRMaster Mix enzyme PCR amplification, PCR reaction system: 98 ℃ 1min, 98 ℃ 10s, 65 ℃ 10s, 72 ℃ 2min, 72 ℃ 5min, 35 cycles. The obtained amplified products were subjected to 1% agarose gel electrophoresis (SYBR Safe DNA Gel Stain, 10,000×), and the agarose gel containing the target DNA band was cut out. The target fragment was recovered using the OMEGA Gel Extraction Kit and the concentration was determined. The obtained 7-segment PCR products and shuttle vector were added to the centrifuge tube in equal proportions and separated according to Yeastmaker TM The steps of Yeast Transformation System 2 require transformation of yeast for in vivo recombination, plating on SD-trp plates, and culturing at 30°C.

[0074]

[0075]

[0076] 2.4 Cloning and assembly of MPV-F4 gene fragments

[0077] Using the synthesized plasmid as template, use the 8 pairs of primers in the table below and use 2×PlatinumTM SuperFi TM II PCRMaster Mix enzyme PCR amplification, PCR reaction system: 98 ℃ 1min, 98 ℃ 10s, 65 ℃ 10s, 72 ℃ 2min, 72 ℃ 5min, 35 cycles. The obtained amplified products were subjected to 1% agarose gel electrophoresis (SYBR Safe DNA Gel Stain, 10,000×), and the agarose gel containing the target DNA band was cut out. The target fragment was recovered using the OMEGA Gel Extraction Kit and the concentration was determined. The obtained 8 PCR products and shuttle vectors were added to the centrifuge tube in equal proportions and the Yeastmaker TM The steps of Yeast Transformation System 2 require transformation of yeast for in vivo recombination, plating on SD-trp plates, and culturing at 30°C.

[0078]

[0079] 2.5 Cloning and assembly of MPV-F5-A9R-A24R-KO gene fragment

[0080] Using the synthesized plasmid as template, use the 8 pairs of primers in the table below and use 2×Platinum TM SuperFi TM II PCRMaster Mix enzyme PCR amplification, PCR reaction system: 98 ℃ 1min, 98 ℃ 10s, 65 ℃ 10s, 72 ℃ 2min, 72 ℃ 5min, 35 cycles. The obtained amplified products were subjected to 1% agarose gel electrophoresis (SYBR Safe DNA Gel Stain, 10,000×), and the agarose gel containing the target DNA band was cut out. The target fragment was recovered using the OMEGA Gel Extraction Kit and the concentration was determined. The obtained 8 PCR products and shuttle vectors were added to the centrifuge tube in equal proportions and the Yeastmaker TM The steps of Yeast Transformation System 2 require transformation of yeast for in vivo recombination, plating on SD-trp plates, and culturing at 30°C.

[0081]

[0082]

[0083] 2.6 Cloning and assembly of MPV-F6-A46R-mNeonGreen gene fragment

[0084] Using the synthesized plasmid as template, use the 8 pairs of primers in the table below and use 2×Platinum TM SuperFi TM II PCRMaster Mix enzyme PCR amplification, PCR reaction system: 98 ℃ 1min, 98 ℃ 10s, 65 ℃ 10s, 72 ℃ 2min, 72 ℃ 5min, 35 cycles. The obtained amplified products were subjected to 1% agarose gel electrophoresis (SYBR Safe DNA Gel Stain, 10,000×), and the agarose gel containing the target DNA band was cut out. The target fragment was recovered using the OMEGA Gel Extraction Kit and the concentration was determined. The obtained 8 PCR products and shuttle vectors were added to the centrifuge tube in equal proportions and the Yeastmaker TM The steps of Yeast Transformation System 2 require transformation of yeast for in vivo recombination, plating on SD-trp plates, and culturing at 30°C.

[0085]

[0086] 2.7 Cloning and assembly of MPV-F7 gene fragments

[0087] Using the synthesized plasmid as a template, use the 8 pairs of primers in the table below to amplify with Q5 High-Fidelity DNA Polymerase PCR. The PCR reaction system is: 98℃5min, 98℃70s, 65℃30s, 72℃3min, 72℃5min, 35 cycles. The obtained amplified product was subjected to 7% agarose gel electrophoresis (SYBR Safe DNA Gel Stain, 70,000×), and the target DNA fragment was recovered using the OMEGA Gel Extraction Kit and the concentration was determined. The obtained 8 PCR products and shuttle vectors were added to a centrifuge tube in equal proportions and separated according to Yeastmaker TM The steps of Yeast Transformation System 2 require transformation of yeast for in vivo recombination, plating on SD / -trp plates and culturing at 30°C.

[0088]

[0089]

[0090] 3. Identification of MPV viral gene fragments

[0091] 3.1 Identification of MPV-F1 gene fragments

[0092] After culturing the SD / -trp plates in 2.1 at 30°C for 2-3 days, randomly pick a single yeast clone to a 4×4 small dish for small-scale amplification culture. The next day, randomly pick a yeast clone to a PCR tube containing 10 μL yeast lysis solution, and use a PCR instrument to lyse the yeast at 94°C for 10 minutes. Using the yeast lysate as a template and the primers in the table below, PCR amplify Bac-F1, F1ab, F1bc, F1cd, F1de, F1ef, F1fg, F1gh, F1hi, and F1i-Bac for verification. The PCR reaction system is: 95°C for 3 min, 95°C for 15 s, 55°C for 15 s, 72°C for 1 min, 72°C for 5 min, and 34 cycles. Refer to the table below and Figure 3 A.

[0093]

[0094] 3.2 Identification of MPV-F2 gene fragments

[0095] After culturing the SD / -trp plates in 2.2 at 30°C for 2-3 days, randomly pick a single yeast clone to a 4×4 small dish for small-scale amplification culture. The next day, randomly pick a yeast clone to a PCR tube containing 10 μL yeast lysis solution, and use a PCR instrument to lyse the yeast at 94°C for 10 minutes. Using the yeast lysate as a template and the primers in the table below, PCR amplify Bac-F2, F2ab, F2bc, F2cd, F2de, F2ef, F2fg, F2gh, and F2h-Bac for verification. The PCR reaction system is: 95°C for 3 min, 95°C for 15 s, 55°C for 15 s, 72°C for 1 min, 72°C for 5 min, and 32 cycles. Refer to the table below and for the identification results. Figure 3 b.

[0096]

[0097]

[0098] 3.3F3-G9R-KO-mcherry gene fragment identification

[0099] After culturing the SD / -trp plates in 2.3 at 30°C for 2-3 days, randomly pick a single yeast clone to a 4×4 small dish for small-scale amplification culture. The next day, randomly pick a yeast clone to a PCR tube containing 10 μL yeast lysis solution, and use a PCR instrument to lyse the yeast at 94°C for 10 minutes. Using the yeast lysate as a template and the primers in the table below, PCR amplify Bac-F3, F3ab, F3bc, F3cd, F3de, F3ef, F3fg, and F3g-Bac for verification. The PCR reaction system is: 95°C for 3 min, 95°C for 15 s, 55°C for 15 s, 72°C for 1 min, 72°C for 5 min, and 32 cycles. Refer to the table below and for the identification results. Figure 3 c.

[0100]

[0101] 3.4 Identification of MPV-F4 gene fragments

[0102] After culturing the SD / -trp plates in 2.4 at 30°C for 2-3 days, randomly pick a single yeast clone to a 4×4 small dish for small-scale amplification culture. The next day, randomly pick a yeast clone to a PCR tube containing 10 μL yeast lysis solution, and use a PCR instrument to lyse the yeast at 94°C for 10 minutes. Using the yeast lysate as a template and the primers in the table below, PCR amplify Bac-F4, F4ab, F4bc, F4cd, F4de, F4ef, F4fg, F4gh, and F4h-Bac for verification. The PCR reaction system is: 95°C for 3 min, 95°C for 15 s, 55°C for 15 s, 72°C for 1 min, 72°C for 5 min, and 32 cycles. Refer to the table below and for the identification results. Figure 3 D.

[0103]

[0104]

[0105] 3.5 Identification of MPV-F5-A9R-A24R-KO gene fragment

[0106] After culturing the SD / -trp plates in 2.5 at 30°C for 2-3 days, randomly pick a single yeast clone to a 4×4 small dish for small-scale amplification culture. The next day, randomly pick a yeast clone to a PCR tube containing 10 μL yeast lysis solution, and use a PCR instrument to lyse the yeast at 94°C for 10 minutes. Using the yeast lysate as a template and the primers in the table below, PCR amplify Bac-F5, F5ab, F5bc, F5cd, F5de, F5ef, F5fg, F5gh, and F5h-Bac for verification. The PCR reaction system is: 95°C for 3 min, 95°C for 15 s, 55°C for 15 s, 72°C for 1 min, 72°C for 5 min, and 32 cycles. Refer to the table below and for the identification results. Figure 3 E.

[0107]

[0108] 3.6 Identification of MPV-F6-A46R-mNeonGreen gene fragment

[0109] After culturing the SD / -trp plates in 2.6 at 30°C for 2-3 days, randomly pick a single yeast clone to a 4×4 small dish for small-scale amplification culture. The next day, randomly pick a yeast clone to a PCR tube containing 10 μL yeast lysis solution, and use a PCR instrument to lyse the yeast at 94°C for 10 minutes. Using the yeast lysate as a template and the primers in the table below, PCR amplify Bac-F6, F6ab, F6bc, F6cd, F6de, F6ef, F6fg, F6gh, and F6h-Bac for verification. The PCR reaction system is: 95°C for 3 min, 95°C for 15 s, 55°C for 15 s, 72°C for 1 min, 72°C for 5 min, and 32 cycles. Refer to the table below and for the identification results. Figure 3 f.

[0110]

[0111]

[0112] 3.7 Identification of MPV-F7 gene fragments

[0113] After culturing the SD / -trp plates in 2.7 at 30°C for 2-3 days, randomly pick a single yeast clone to a 4×4 small dish for small-scale amplification culture. The next day, randomly pick a yeast clone to a PCR tube containing 10 μL yeast lysis solution, and use a PCR instrument to lyse the yeast at 94°C for 10 minutes. Using the yeast lysate as a template and the primers in the table below, PCR amplify Bac-F7, F7ab, F7bc, F7cd, F7de, F7ef, F7fg, F7gh, and F7h-Bac for verification. The PCR reaction system is: 95°C for 3 min, 95°C for 15 s, 55°C for 15 s, 72°C for 1 min, 72°C for 5 min, and 34 cycles. Refer to the table below and for the identification results. Figure 3 g.

[0114]

[0115] 4. MPV virus gene cloning yeast extraction

[0116] The yeast clones verified by PCR were amplified and cultured, and the yeast colonies were collected into 1.5 mL Eppendorf tubes containing 500 μL 10 mM EDTA. Yeast DNA was extracted according to the instructions of Easy Yeast Plasmid Isolation Kit (630467, TAKARA).

[0117] 5. MPV gene cloning and bacterial transformation

[0118] Take out the competent BOR cells from the -80℃ refrigerator and thaw them on ice; take 5μL of MPV viral DNA extracted from yeast into the competent BOR cells, mix carefully and add it to the pre-cooled 0.2CM electrode cup, tap the electrode cup gently to make the mixture evenly enter the bottom of the electrode cup, and place it on ice for 5min. Turn on the electroporator and adjust the parameters voltage: 2.5KV, capacitance: 25μF, resistance: 300Ω, cuvette: 2mm. Push the electrode cup into the electroporator, press the pulse key, and after hearing the beep, quickly add 1000μL of SOC liquid culture medium to the electroporator cup, resuspend the cells, and transfer them to a 1.5mL centrifuge tube. Resuscitate at 37℃, 220rpm for 1 hour. Centrifuge at 4000rpm for 5min, remove most of the supernatant culture medium and leave about 200μL SOC coated plate, place in a 37℃ incubator, culture overnight, and check the transformation results the next day.

[0119] 6. MPV virus gene cloning plasmid extraction

[0120] Dip the culture medium and streak, pick a single clone and culture it in 5mL LB medium overnight, then transfer it to 1L LB medium for further culture.600 When the pH reached 0.3, 1 mL of inducer was added to induce plasmid amplification for about 8 hours. After induction, the bacteria were collected and plasmid DNA was extracted using the Tiangen Endotoxin-free Plasmid Extraction Kit (DP117) according to the operating instructions.

[0121] 7.MPV virus gene cloning plasmid enzyme digestion and gel recovery

[0122] The enzyme digestion system is as follows:

[0123]

[0124] The plasmid extracted in 6 was mixed according to the above system and incubated at 37℃ for 8 hours or overnight. The enzyme digestion products were subjected to 0.6-0.8% agarose gel electrophoresis at 80V for 2 hours. Figure 4 As expected, two fragments were cut out from each plasmid: the vector (lower band) and the MPV subgene clone DNA fragment (upper band). The target fragments were recovered using the OMEGA Gel&PCR Clean Kit and the concentration was determined.

[0125] 8. In vitro ligation of the entire MPV virus genome

[0126] The monkeypox virus subgene fragments recovered by PaqCI digestion in 7 were subjected to T4 in vitro ligation at an equimolar concentration ratio (0.1pmol / fragment). First, the monkeypox virus subgene fragments were divided into three groups: Group A, Group B, and Group C. Group A connected Hairpin, MPV-F1, and MPV-F2 together; Group B connected MPV-F3-G9R-KO-mCherry, MPV-F4, and MPV-F5-A9R-A24R-KO together; Group C connected MPV-F6-A46R-mNeonGreen, MPV-F7, and Hairpin together.

[0127] The ligation reaction system is as follows:

[0128]

[0129] After the ligation reaction was placed at 4°C for 16 to 20 hours, the three groups of ligation products were combined into one tube and continued to be ligated in vitro for 16 to 20 hours. The ligation product, i.e., the full-length genome of monkeypox virus, was recovered by DNA electrophoresis.

[0130] refer to Figure 5In the above steps of this embodiment, the 57 small fragments of the monkeypox virus subgenome synthesized by gene were first integrated into 7 large fragments by Gibson assembly and yeast in vivo recombination, and then spliced ​​into a complete defective monkeypox virus genome by in vitro T4 enzyme ligation. Subsequently, the connection points of each fragment were verified by PCR, and then the whole genome sequencing was used to confirm that the integrity of the defective genome was correct and no other additional mutations were introduced.

[0131] Example 3: MPV virus cell transfection

[0132] refer to Figure 6 FIG. a is a schematic diagram of a rescue strategy for defective monkeypox virus in this embodiment, and the specific steps are as follows:

[0133] The day before the rescue of replication-deficient virus, the VeroE6-G9R-A9R-A24R cells of the monkeypox virus essential gene complementation cell line established in Example 1 were digested and then cultured at 2×10 6 / well for plating. Before transfection with full-length viral DNA, cells were infected with 0.1 MOI fowlpox virus (fowlpox virus quail attenuated strain, CVCC AV1003) to provide poxvirus RNA transcriptase (conserved in poxviruses) to initiate the expression of early genes of the defective monkeypox genome. After 4 hours of fowlpox virus infection, the viral supernatant was discarded and washed 3 times with PBS, and 400 μL Opti-MEM was added to each well.

[0134] The defective monkeypox virus full-length genome DNA obtained by ligation in the previous step was connected to 6. The transfection reagent was mixed at a ratio of 1:3 for DNA: transfection reagent. After incubation at room temperature for 15 minutes, 1 μg / well of the full-length defective monkeypox virus obtained by splicing according to Example 2 was added dropwise to the cells infected with fowlpox virus for transfection. After 6 hours, fresh 2% FBSDMEM medium was replaced for culture. After transfection, the fluorescent protein expression and cytopathic effect (CPE) of the cells were observed every day from Day 1 to Day 12.

[0135] Reference for fluorescence microscopy observation results Figure 6b, the expression of viral fluorescent protein and viral CPE appeared within 5 to 7 days. Plaques with red and green fluorescence can be seen on the 5th day after transfection, and the expansion and spread of plaques can be observed from the 7th to the 9th day. The peripheral cells of the plaques are in the early stage of infection, and only mCherry controlled by the mid-term gene promoter is activated, while the internal infected cells activate mNeonGreen controlled by the late gene promoter. After a large number of cells show obvious lesions, the virus supernatant and cells (P0 generation virus) are collected. The cells are broken by freezing and thawing, and the cell lysate is expanded and inoculated into a new complement cell line to observe cell lesions and fluorescence changes. The P1 generation replication-deficient virus is collected and its titer is determined.

[0136] Example 4: Immunoblotting validation

[0137] The product in Example 3 was identified by immunoblotting using a mouse monoclonal antibody against the monkeypox virus A35R protein, and protein electrophoresis was performed using complementary cell lysate without fowlpox virus or monkeypox virus DNA transfection as a control group and a cell lysate of the infected group. Figure 7 As shown in the figure, it can be seen that compared with the control group, the supernatant of the infected group showed obvious viral A35R protein color development, proving that the complementary defective monkeypox virus can be rescued in a cell line that stably expresses viral proteins.

[0138] Example 5: Safety evaluation of replication-defective monkeypox virus

[0139] Referring to Example 3, the P1 virus in Example 3 was used to infect different types of cells including Vero E6G9R-A9R-A24R, Caco2, 22RV1, RK13, LLC-MK2, Huh7, Vero E6, SW13, 15P-1, A549, 293T, Neuro-2a, etc. at a virus titer of 0.01 MOI to identify the safety of the virus in other non-complementary cell lines. Figure 8 The replication-defective monkeypox virus only grows in the complementary cell line Vero E6G9R-A9R-A24R that expresses the key viral genes, and cannot grow in any other non-complementary cell lines such as Caco2, 293T, etc.

[0140] Example 6: Construction of G9R and A1L double gene knockout monkeypox defective virus

[0141] Referring to the preparation process of the above-mentioned embodiment, a monkeypox defective virus with double knockout of G9R and A1L genes was constructed: the F4f of the MPV-F4 clone in 2.4 of Example 2 was replaced with a new F4f fragment with the A1L gene deleted by gene synthesis to construct an MPV-F4-A1L-KO clone with the A1L gene deleted; and the F5a fragment of the MPV-F5-A9R-A24R-KO gene clone in 2.5 was replaced with a new F5a with a complete monkeypox virus A9R gene synthesized by gene synthesis, and the F5e fragment was replaced with a new F5e with a complete monkeypox virus A24R gene synthesized by gene synthesis, and finally an MPV-F5 clone with complete monkeypox virus genes A9R and A24R was constructed. In this way, the whole gene of the MPV-G9R-A1L-KO virus was connected in vitro with reference to the scheme in Example 2.

[0142] The Vero-G9R-A1L complementing cell line of essential genes G9R and A1L of monkeypox virus was established by referring to the scheme in Example 1, and the MPV-G9R-A1L-KO virus packaging and rescue was performed in the Vero-G9R-A1L complementing cell line by referring to the scheme in Example 3.

[0143] The product was immunoblotted for identification in reference example 3, and the results showed that compared with the control group, the supernatant of the infection group showed obvious viral A35R protein coloring, proving that the complementary defective monkeypox virus can be rescued in the cell line stably expressing the viral protein. Safety identification was performed in reference example 5, and the results showed that the replication-deficient monkeypox virus only grew in the complementary cell line Vero-G9R-A1L expressing the key viral gene, and could not grow in any other non-complementary cell line such as Caco2, 293T, etc.

[0144] Based on the above results, it can be seen that the reverse genetics research method was used in this application to construct a trans-complementation defective virus system of monkeypox virus for the first time; by producing progeny viruses with replication defects, the biosafety level 3 monkeypox virus can be used for relevant scientific research under biosafety level 2 and below safety conditions, ensuring the safety of researchers, reducing the risk of mutation research on monkeypox virus, and providing an important platform for high-throughput screening and evaluation of anti-monkeypox virus drugs.

[0145] The defective progeny virus produced by the monkeypox trans-complementation system is almost identical to the real live virus in terms of physical and chemical properties. In the complementary cell line, the whole process of virus invasion, replication, packaging and release can be completed, which has natural advantages over other virus systems. While ensuring safety, various basic research on monkeypox virus can be carried out, and anti-monkeypox virus drug screening, neutralizing antibody evaluation, vaccine protection evaluation and attenuated vaccine development can be carried out.

[0146] The present application is described in detail above in conjunction with the embodiments, but the present application is not limited to the above embodiments, and various changes can be made within the knowledge of ordinary technicians in the relevant technical field without departing from the purpose of the present application. In addition, the embodiments of the present application and the features in the embodiments can be combined with each other without conflict.

Claims

1. Trans-complementation defective monkeypox virus system, It is characterized in that include: Biological material, wherein the biological material is selected from any one of the following A1) to A4): A1) An isolated nucleic acid molecule comprising a nucleic acid sequence of the entire genome of a monkeypox virus, wherein the nucleic acid sequence lacks a plurality of genes; A2) an expression cassette comprising the nucleic acid molecule described in A1); A3) a vector comprising the nucleic acid molecule described in A1); A4) a cell comprising the nucleic acid molecule described in A1); anaplerotic cells, wherein the anaplerotic cells express a plurality of genes missing from the biomaterial; The GenBank accession number of the nucleic acid sequence of the whole genome of the monkeypox virus is ON563414.3; the multiple genes are A9R, A24R and G9R, or the multiple genes are A1L and G9R.

2. A method for producing replication-defective monkeypox virus using the trans-complementation-defective monkeypox virus system according to claim 1, It is characterized in that The following steps are involved: Infecting the complemented cells with the defective monkeypox virus to rescue the replication-defective monkeypox virus; The nucleic acid sequence of the whole genome of the defective monkeypox virus lacks multiple genes, and the complemented cells express the multiple genes; The GenBank accession number of the nucleic acid sequence of the whole genome of the monkeypox virus is ON563414.3; the multiple genes are A9R, A24R and G9R, or the multiple genes are A1L and G9R.

3. The method according to claim 2, It is characterized in that The defective monkeypox virus is prepared by a method comprising the following steps: Knocking out the multiple genes from the full-length gene of the monkeypox virus, and inserting a reporter gene to obtain a defective full-length gene of the monkeypox virus; The defective monkeypox virus full-length gene is split, primers are designed to amplify them respectively, and they are cloned into recombinant vectors respectively by homologous recombination; After the recombinant vector is digested by enzyme, it is connected with ligase to obtain a full-length clone of the monkeypox virus genome with the multiple genes knocked out; The full-length clone is transfected into cells to obtain defective monkeypox virus.

4. The method according to claim 3, It is characterized in that The defective monkeypox virus full-length gene is split, primers are designed to be amplified respectively, and cloned into a recombinant vector respectively by homologous recombination method, including: The defective monkeypox virus full-length gene is split into gene fragments with a length of 1000-5000 bp, and amplification primers are designed respectively; amplifying the gene fragment using the amplification primers to obtain different amplification products; The amplified product is cloned into a recombinant vector by homologous recombination to obtain 5 to 10 recombinant vectors containing different spliced ​​fragments with a length of 1 to 30 kb.

5. The method according to claim 4, It is characterized in that The amplification primers are shown in SEQ No.1~112.

6. The method according to claim 2, It is characterized in that The anaplerotic cells are prepared by a method comprising the following steps: inserting several genes among the multiple genes of the monkeypox virus into a first lentiviral vector for packaging after codon optimization, collecting the first lentivirus and infecting the first cell, and screening to obtain the first cell expressing the several genes; The remaining genes of the multiple genes of the monkeypox virus are inserted into a second lentiviral vector for packaging after codon optimization, the second lentivirus is collected and used to infect the first cells expressing the several genes, and the complemented cells are screened.

7. A replication-defective monkeypox virus obtained by the method according to any one of claims 2 to 6.

8. Use of the trans-complemented monkeypox virus system of claim 1 or the replication-defective monkeypox virus of claim 7 in the preparation of a product for screening anti-monkeypox virus drugs, a product for evaluating the efficacy of anti-monkeypox virus drugs, or a drug for preventing and / or treating monkeypox virus.